← Leaderboards
Akrit Singh Sodhi
Johns Hopkins University
$6,040,861
Attributed
$7,176,717
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,176,717 · 5
By mechanism
R01$5,828,519 · 3
K08$897,885 · 1
R21$450,313 · 1
Top collaborators
- Silvia V Montaner4 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Jun O. Liu$22,989,575
- Stanley A Vinores$2,405,911
- Iulian Ioan Iordachita$5,636,644
- Peter Louis Gehlbach$2,476,888
- Marin Kobilarov$433,293
Others in their field
Top investigators on “Insight”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- James Dennis Neaton · Northwestern University$283,212,546
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$278,513,775
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$200,435,757
Research focus
InsightMolecularRetinaHypoxiaIn VivoRetinal DiseasesVascular Endothelial Growth FactorsTissuesNeovascularizationBlindnessTargeted TreatmentGrowthBlood VesselsDiabeticHypoxia Inducible FactorHypoxia Inducible Factor 1NeovascularResponseAngiogenic FactorIn VitroEye DiseasesCell MotilityPathologic NeovascularizationEffective Therapy
Grant awards (18)
Hypoxia Inducible Factors and Hypoglycemia in Early Diabetic Eye Disease$472,725
R01 · FY2025 · EY · contact PI
Elucidation of novel anti-angiogenic therapies for the prevention and treatment of neovascular glaucoma$584,568
R01 · FY2024 · EY
Hypoxia Inducible Factors and Hypoglycemia in Early Diabetic Eye Disease$470,039
R01 · FY2024 · EY · contact PI
Molecular Engineering of Novel Therapies to Treat Corneal Neovascularization$204,688
R21 · FY2024 · EY · contact PI
Elucidation of novel anti-angiogenic therapies for the prevention and treatment of neovascular glaucoma$578,018
R01 · FY2023 · EY
Divergent Roles for Hypoxia-Inducible Factor-1 and -2 in Ischemic Retinal Disease$530,319
R01 · FY2023 · EY · contact PI
Molecular Engineering of Novel Therapies to Treat Corneal Neovascularization$245,625
R21 · FY2023 · EY · contact PI
Elucidation of novel anti-angiogenic therapies for the prevention and treatment of neovascular glaucoma$557,501
R01 · FY2022 · EY
Divergent Roles for Hypoxia-Inducible Factor-1 and -2 in Ischemic Retinal Disease$514,408
R01 · FY2022 · EY · contact PI
Elucidation of novel anti-angiogenic therapies for the prevention and treatment of neovascular glaucoma$551,625
R01 · FY2021 · EY
Divergent Roles for Hypoxia-Inducible Factor-1 and -2 in Ischemic Retinal Disease$514,409
R01 · FY2021 · EY · contact PI
Divergent Roles for Hypoxia-Inducible Factor-1 and -2 in Ischemic Retinal Disease$530,319
R01 · FY2020 · EY · contact PI
Divergent Roles for Hypoxia-Inducible Factor-1 and -2 in Ischemic Retinal Disease$524,588
R01 · FY2019 · EY · contact PI
HIF dysregulation as a novel genetic model to study retinal neovascular disease.$179,577
K08 · FY2015 · EY · contact PI
HIF dysregulation as a novel genetic model to study retinal neovascular disease.$179,577
K08 · FY2014 · EY · contact PI
HIF dysregulation as a novel genetic model to study retinal neovascular disease.$179,577
K08 · FY2013 · EY · contact PI
HIF dysregulation as a novel genetic model to study retinal neovascular disease.$179,577
K08 · FY2012 · EY · contact PI
HIF dysregulation as a novel genetic model to study retinal neovascular disease.$179,577
K08 · FY2011 · EY · contact PI